ClinicalTrials.gg

Program

bezisterim

Also written as “HE3286” and “NE3107”.

Its studies are mostly in Parkinson Disease · Insulin Resistance · Post-Acute COVID-19 Syndrome · Alzheimer Disease · Diabetes Mellitus, Type 2, led by 2 companies.

Furthest: phase 3, since Feb 25, 20089 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Harbor Therapeutics50 open or runningphase 2since Feb 25, 2008Nov 6, 2007none ahead
BioVie40 open or runningphase 3since Dec 4, 2020Dec 4, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 6, 2007First study: phase 1 study in Insulin ResistanceNew to Harbor TherapeuticsHarbor Therapeutics · NCT00555451 · 66 enrolled · United States
  2. Feb 25, 2008Phase 2 study in Colitis, UlcerativeHarbor Therapeutics · NCT00628433 · 27 enrolled · United States
  3. Jun 6, 2008Phase 2 study in Diabetes Mellitus, Type 2Harbor Therapeutics · NCT00694057 · 164 enrolled · United States
  4. Jul 6, 2008Phase 2 study in Arthritis, RheumatoidHarbor Therapeutics · NCT00712114 · 14 enrolled · United States
  5. Oct 5, 2009Phase 1 study in Insulin ResistanceHarbor Therapeutics · NCT00991107 · 5 enrolled · United States
  6. Dec 4, 2020BioVie's first study: phase 3 study in Alzheimer DiseaseNew to BioVieBioVie · NCT04669028 · 439 enrolled · United States
  7. Sep 23, 2021Phase 2 study in Parkinson DiseaseBioVie · NCT05083260 · 46 enrolled · United States
  8. Dec 24, 2024Phase 2 study in Parkinson DiseaseBioVie · NCT06757010 · 57 enrolled · United States
  9. Feb 24, 2025Phase 2 study in Post-Acute COVID-19 SyndromeBioVie · NCT06847191 · 203 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06847191Post-Acute COVID-19 Syndrome · United States2CompletedBioVieAug 6, 2026203
NCT06757010Parkinson Disease · United States2CompletedBioVieMay 1, 202657
NCT05083260Parkinson Disease · United States2CompletedBioVieNov 21, 202246
NCT04669028Alzheimer Disease · United States3CompletedBioVieSep 30, 2023439
NCT00991107Insulin Resistance · United States1CompletedHarbor TherapeuticsAug 20105
NCT00712114Arthritis, Rheumatoid · United States2CompletedHarbor TherapeuticsJul 200914
NCT00694057Diabetes Mellitus, Type 2 · United States2CompletedHarbor TherapeuticsJan 2010164
NCT00628433Colitis, Ulcerative · United States2CompletedHarbor TherapeuticsMay 200927
NCT00555451Insulin Resistance · United States1CompletedHarbor TherapeuticsSep 200966

How it is read

Names in the registry

  • “HE3286”, 7 entries
  • “NE3107”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.